SystImmune and Bristol Myers Squibb announced that they have entered into an exclusive global license and collaboration agreement for SystImmune’s BL-B01D1, a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate. Under the agreement the companies will jointly develop and commercialise BL-B01D1 in the US. SystImmune through its affiliates will be responsible for development, manufacturing and commercialisation in China and will be responsible for manufacturing certain drug supplies for use outside of China. BMS will be responsible for development and commercialisation of BL-B01D1 in the rest of the world.
BL-B01D1 is currently being evaluated in a global phase I study (BL-B01D1-LUNG101) for safety and efficacy in individuals with metastatic or unresectable non-small cell lung cancer (NSCLC).